DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients

计划入组 100 人 · 首次发布于 2024 年 4 月 29 日

Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing

计划入组 55 人 · 首次发布于 2021 年 7 月 20 日

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

计划入组 65 人 · 首次发布于 2023 年 8 月 4 日

TKA-731

TKA-457

X-Synergy®

GENOMIC HEALTH, INC.

United States

Theralase Technologies Inc

Canada

TKC

DiviTum® TKa Blood Test Shows Promise in Predicting Immunotherapy Response Across Multiple Cancers

Biovica Expands Oncology Partnership with US Biotech Firm in SEK 2.5M TKa Testing Deal

Biovica Signs Master Service Agreement to Support Next-Generation CDK4/6 Inhibitor Development for Breast Cancer